Research consistently demonstrates the superior performance of PSMA-targeted imaging agents compared to other molecular tracers, such as fluoride, fluciclovine, and choline, particularly in patients with biochemical recurrence of prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.